ScreenerHero

KPTIKaryopharm Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · karyopharm.com
1.960USD-2.00%Mkt Cap: 44.46M $P/E: —

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap44.46M $
Enterprise Value304.71M $
Revenue (TTM)146.62M $
Gross Profit140.12M $
Net Income (TTM)-196.04M $
Revenue/Share7.554 USD
Last Price1.960 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees228
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS48576U1060
Valuation
P/E (Trailing)—
P/E (Forward)-0.65
PEG—
EV/EBITDA-3.71
EV/Revenue2.08
P/S0.28
P/B-0.13
EPS (TTM)-13.15
EPS (Forward)-2.82
52W Range
1.7902% of range10.99
52W High10.99 USD
52W Low1.790 USD
Profitability
Gross Margin95.93%
Oper. Margin-67.38%
EBITDA Margin-56.06%
Profit Margin-134.21%
ROE66.92%
ROA-180.82%
Growth
Revenue Growth-11.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-75.37M $
CapEx (TTM)—
FCF Margin-20.24%
FCF Yield-66.75%
Net Debt263.42M $
Net Debt/EBITDA-3.20
Balance Sheet
Debt/Equity-0.80
Current Ratio0.79
Quick Ratio0.71
Book Value/Sh-14.5570 USD
Cash/Share2.870 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateFeb 26, 2025
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.250 USD
Upside (mean)+269.9%
Target Range3.000 USD – 11.00 USD
$3.000+269.9% to mean$11.00
# Analysts4
Ownership
Shares Out.22.68M
Float17.07M
Insiders4.67%
Institutions93.70%
Short Interest
Short Ratio4.5d
Short % Float33.51%
Short % Out.33.34%
Shares Short7.56M
Short (prev mo.)6.58M
Technical
SMA 506.903 (-71.6%)
SMA 2007.339 (-73.3%)
Beta0.94
S&P 52W Chg18.16%
Avg Vol (30d)1.88M
Avg Vol (10d)1.42M
Technical Indicators
RSI (14)22.1
MACD-1.6253
MACD Signal-1.6988
MACD Hist.+0.0735
BB Upper8.326 USD
BB Middle3.513 USD
BB Lower-1.3007 USD
BB Width274.06%
ATR (14)0.5173 USD
Vol Ratio (20d)0.35x